{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:06:33Z","timestamp":1780988793437,"version":"3.54.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2026,6,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>The growing burden of drug-resistant mycobacterial infections demands\nnovel therapeutic agents. One strategy for discovering new tuberculosis (TB) drugs is to target essential\nproteins within validated biosynthetic pathways. FadD32 is a key enzyme in mycolic acid synthesis\nand is critical for the viability of Mycobacterium tuberculosis (Mtb). Accordingly, identifying\npotent FadD32 inhibitors represents a promising approach that may help circumvent resistance to\nexisting TB drugs such as isoniazid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study employed structure-based drug design using molecular docking to evaluate the\nbinding potential of 7-substituted coumarin derivatives and compounds from the Maybridge database\nagainst FadD32. Docking was performed using Hybrid 4.0 software. Top-scoring ligands were\nscreened for antimycobacterial activity against Mycobacterium smegmatis mc\u00b2155 using the Alamar\nBlue assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>All 7-substituted coumarin derivatives exhibited better docking scores than the native ligand\nof FadD32. Additionally, 14 Maybridge compounds, including diverse scaffolds, also showed favorable\ndocking results. Among them, HTS08202 (a benzimidazole derivative) demonstrated significant\nactivity, inhibiting M. smegmatis mc2155 by 94.12% (\u00b12.34%) and 94.82% (\u00b11.73%) at 50 \u03bcM and\n25 \u03bcM, respectively. CP15, a coumarin-based compound, achieved 82.38% (\u00b13.18%) inhibition at 50\n\u03bcM. Cytotoxicity assessment revealed that HTS08202 was not toxic at 25 \u03bcM, its active concentration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>The findings highlight the potential of both benzimidazole and coumarin-based derivatives\nas promising leads for antimycobacterial drug development. The favorable docking scores and\nbiological activity suggest that FadD32 inhibition may be a viable strategy to overcome resistance\nmechanisms in TB. HTS08202 stands out for its higher inhibition and lower cytotoxicity, and requires\nfurther optimization and in vivo evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The identified compounds, especially HTS08202 merit further investigation as potential\nantimycobacterial agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115672018429133260523070144","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:26:26Z","timestamp":1780986386000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigating FadD32 as a Target for 7-Substituted Coumarin Derivatives and Other Potential Antimycobacterial Agents"],"prefix":"10.2174","volume":"23","author":[{"given":"Sean","family":"Shamido","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, School of Pharmacy, University of the Western Cape, Private Bag X17,Bellville 7535, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Joubert","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, School of Pharmacy, University of the Western Cape, Private Bag X17,Bellville 7535, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Sampson","sequence":"additional","affiliation":[{"name":"DSTI\/NRF Centre of Excellence in Biomedical Tuberculosis Research, SA MRC Centrefor Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and HealthSciences, University of Stellenbosch, Cape Town, Tygerberg, 7505, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afeez I.","family":"Kareem","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, School of Pharmacy, University of the Western Cape, Private Bag X17,Bellville 7535, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Mari","family":"du Plessis","sequence":"additional","affiliation":[{"name":"DSTI\/NRF Centre of Excellence in Biomedical Tuberculosis Research, SA MRC Centrefor Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and HealthSciences, University of Stellenbosch, Cape Town, Tygerberg, 7505, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Kapp","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, School of Pharmacy, University of the Western Cape, Private Bag X17,Bellville 7535, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672018429133260523070144","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/254867\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672018429133260523070144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:26:30Z","timestamp":1780986390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/254867\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115672018429133260523070144","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}